Signal Breakdown
8 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- JPMorgan raised Danaher's price target from $250 to $270 and maintained an overweight rating.
- NBT Bank bought 38,634 Danaher shares (~$8.559M) in Q3, indicating institutional buying interest.
- Masimo received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable, expanding diagnostics capabilities.
Risk Factors
- Private Wealth Partners trimmed its Danaher stake 5.0% in Q3, selling 4,416 shares.
- Howland Capital reduced its Danaher stake by 4.4% in Q3, selling 7,662 shares.
- An existing director will retire as Danaher adds two new board members, signaling a governance refresh.
Evidence
- 2026-10-25Source: TIINGO
Summary: JPMorgan raised Danaher's price target from $250 to $270 and retains an overweight rating, per Benzinga; other analysts (e.g., UBS) have also issued reports on DHR.
Bullish - 2026-10-24Source: TIINGO
Summary: Private Wealth Partners LLC trimmed its Danaher (DHR) stake 5.0% in Q3, selling 4,416 shares and holding 83,559 shares after the sale; Danaher comprised about 1.3% of the fund’s portfolio per the 13F filing.
Neutral - 2026-10-23Source: TIINGO
Summary: Howland Capital Management reduced its Danaher (DHR) stake by 4.4% in Q3, selling 7,662 shares to hold 166,298 shares; Danaher represents 1.3% of Howland's portfolio.
Neutral - 2026-10-23Source: TIINGO
Summary: NBT Bank N.A. bought 38,634 Danaher (DHR) shares (~$8.559M) in Q3 per its 13F filing, reflecting institutional buying interest as other hedge funds also adjusted positions.
Bullish - 2026-10-23Source: TIINGO
Summary: Danaher reported Q3 2026 sales of $6.55B and net income of $1.24B; an earnings beat briefly lifted the stock. Shares are down 1.76% one day but up 19.97% over 90 days, and the piece suggests the stock may be ~6% undervalued.
Bullish - 2026-10-22Source: TIINGO
Summary: Compares GE HealthCare to Danaher (DHR) and Medtronic, highlighting GEHC's $23.9B backlog and AI innovation; Danaher is only a comparator with no new Danaher-specific financials, products, or guidance — neutral for DHR.
Neutral - 2026-10-22Source: TIINGO
Summary: Masimo, a Danaher subsidiary, received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable for acute care, adding a digital monitoring capability that could boost Danaher’s diagnostics portfolio and market competitiveness.
Bullish
Showing 7 of 8 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.